Health
Monoclonal antibodies against MERS coronavirus show promise in phase 1 trial – Medical Xpress
A randomized, placebo-controlled Phase 1 clinical trial of two monoclonal antibodies (mAbs) directed against the coronavirus that causes Middle East respiratory…
A randomized, placebo-controlled Phase 1 clinical trial of two monoclonal antibodies (mAbs) directed against the coronavirus that causes Middle East respiratory syndrome (MERS) found that they were well tolerated and generally safe when administered simultaneously to healthy adults. The experimental mAbs, REGN3048 and REGN3051, target the MERS coronavirus (MERS CoV) spike protein used by the virus to attach to and infect target cells. The mAbs were discovered and developed by scientists at the biopharmaceutical…
-
Noosa News17 hours agoLuxury caravan manufacturer Zone RV collapses into administration
-
General18 hours agoWoman in her 20s dies after dog attack in Western Australia’s north
-
General24 hours agoGold Coast warned it faces traffic gridlock without major shift to public transport
-
General16 hours agoCase against teens charged over Adelaide shopping centre stabbing could move to adult court